Company intelligence / Profile preview

DiveRadGel Co., Ltd.

Ownership: Private
Development stage: Preclinical

Overview

DiveRadGel has demonstrated complete regression of "cold" tumors and long-term protection from tumor re-challenge (>18 months) in mouse models, with evidence of potent antigen spreading. GMP-level manufacturing for their DDS technology has been completed, and scale-up to pilot production for the antigen-loaded vaccine is underway.

Therapeutic areas: Oncology
Modalities: Cancer vaccines (antigen-loaded)Drug delivery systems (DDS)Immunotherapy platforms targeting dendritic cells (cDC1s)
Industry: Biotech

Drug pipeline

1 asset

Sonanos

Pre-clinical

Indications: Solid tumors

Partnerships

Seeking co-development partners for antigen-cocktail cancer vaccines using external proprietary epitopes.Open to combination therapy studies with TCR-T cell therapies, radiotherapy, immune checkpoint inhibitors (ICIs), etc.

Beyond the preview

Go deeper on DiveRadGel Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiveRadGel Co., Ltd..

Explore the full profile